Biotek-snakken — Oktober 2017
-
-
-
Biotekselskabet Orphazyme meldes klar til at ramme fondsbørsen i København til november. Det skriver dagbladet Børsen med henvisning til anonyme kilder.
Orphazyme vil angiveligt sælge aktier for 600 mio. kr., og det bliver første gang, der skal nynoteres et biotekselskab i Danmark siden Zealand Pharma i 2010.
Pengene skal ifølge Børsen bruges til at gennemføre de sidste kliniske studier med lægemidler mod to muskelsvindssygdomme.
-
@JKY_VH kender du noget til selskabet, ud over hvad man kan læse i avisen?
-
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to MOR208, in combination with lenalidomide, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation
-
Orphazyme virker spændende da de har 3 kandidater klar til opstart i Fase 3.
-
Expres2ion leverer igen idag en forrygende stigning.
-
Pipeline ser spændende ud.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind